<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30275853</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">1738-6756</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>21</Volume>                    <Issue>3</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of breast cancer</Title>                <ISOAbbreviation>J Breast Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 <i>In Vivo</i>.</ArticleTitle>            <Pagination>                <MedlinePgn>251-258</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4048/jbc.2018.21.e40</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">Multidrug resistance (MDR) remains a major obstacle in the treatment of triple-negative breast cancer (TNBC) with conventional chemotherapeutic agents. A previous study demonstrated that hsa-miRNA-143-3p plays a vital role in drug resistance of TNBC. Downregulation of hsa-miRNA-143-3p upregulated the expression of its target protein cytokine-induced apoptosis inhibitor 1 (CIAPIN1) in order to activate MDR, while upregulation of hsa-miRNA-143-3p effectively enhances the sensitivity of drug-resistant TNBC cells to chemotherapeutics. The present study aimed to further verify these findings <i>in vivo</i>.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">We established a hypodermic tumor nude mice model using paclitaxel-resistant TNBC cells. We expressed ectopic hsa-miRNA-143-3p under the control of a breast cancer-specific human mammaglobin promoter that guided the efficient expression of exogenous hsa-miRNA-143-3p only in breast cancer cells. Thereafter, we overexpressed hsa-miRNA-143-3p in xenografts using a recombinant virus system and quantified the expression of hsa-miRNA-143-3p, CIAPIN1 protein, and proteins encoded by related functional genes by western blot.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">We successfully completed the prospective exploration of the intravenous virus injection pattern from extensive expression to targeted expression. The overexpression of hsa-miRNA-143-3p significantly alleviated chemoresistance of TNBC by inhibiting viability. In addition, we observed that the expression of CIAPIN1 as a hsa-miRNA-143-3p target protein was remarkably decreased.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">We partly illustrated the mechanism underlying the hsa-miRNA-143-3p/CIAPIN1 drug resistance pathway. HsamiRNA-143-3p as a tumor suppressive microRNA may be a novel target to effectively reverse MDR of TNBC <i>in vivo</i>.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Deng</LastName>                    <ForeName>Yu Wei</ForeName>                    <Initials>YW</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Second Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hao</LastName>                    <ForeName>Wen Jing</ForeName>                    <Initials>WJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Second Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Yi Wen</ForeName>                    <Initials>YW</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Second Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Yi Xin</ForeName>                    <Initials>YX</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Second Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Bo Chen</ForeName>                    <Initials>BC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Second Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lu</LastName>                    <ForeName>Dan</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Second Affiliated Hospital of Harbin Medical University, Harbin, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>J Breast Cancer</MedlineTA>            <NlmUniqueID>101314183</NlmUniqueID>            <ISSNLinking>1738-6756</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2016 Aug 9;115(4):431-41</RefSource>                <PMID Version="1">27415012</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Lett. 2017 Jan;13(1):435-440</RefSource>                <PMID Version="1">28123579</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Contemp Oncol (Pozn). 2015;19(6):423-7</RefSource>                <PMID Version="1">26843836</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2011 Apr;25(4):1091-8</RefSource>                <PMID Version="1">21240465</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biotechnol Bioeng. 2018 Jan;115(1):25-40</RefSource>                <PMID Version="1">28941274</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2017 Aug;164(3):649-658</RefSource>                <PMID Version="1">28508185</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2015 Apr;36(4):2737-45</RefSource>                <PMID Version="1">25492481</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Nat Prod. 2018 Mar 23;81(3):600-606</RefSource>                <PMID Version="1">29517223</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Rev Med Pharmacol Sci. 2017 Jul;21(13):3054-3060</RefSource>                <PMID Version="1">28742201</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2015 Sep 8;6(26):22996-3007</RefSource>                <PMID Version="1">26392389</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2017 Nov 20;7(1):15824</RefSource>                <PMID Version="1">29158480</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochemistry (Mosc). 2016 Jul;81(7):700-8</RefSource>                <PMID Version="1">27449616</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Aug 10;9(1):321-331</RefSource>                <PMID Version="1">29416616</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Jan 31;8(5):8622-8632</RefSource>                <PMID Version="1">28052008</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2017 Jul 15;141(2):220-230</RefSource>                <PMID Version="1">28240776</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Molecules. 2017 Apr 08;22(4):</RefSource>                <PMID Version="1">28397762</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Death Dis. 2018 Feb 7;9(2):188</RefSource>                <PMID Version="1">29416005</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Pharmacol. 2016 Jan 1;99:132-45</RefSource>                <PMID Version="1">26679828</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Ther Med. 2017 Aug;14(2):1789-1794</RefSource>                <PMID Version="1">28810651</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Lett. 2017 Jun;13(6):4695-4700</RefSource>                <PMID Version="1">28588724</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Braz J Med Biol Res. 2014 Apr;47(4):273-8</RefSource>                <PMID Version="1">24676475</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Lett. 2017 Jul 1;397:94-102</RefSource>                <PMID Version="1">28254409</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J BUON. 2016 Jan-Feb;21(1):35-41</RefSource>                <PMID Version="1">27061528</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Aug 23;7(34):55900-55911</RefSource>                <PMID Version="1">27344185</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Biol Med (Maywood). 2015 Jul;240(7):867-75</RefSource>                <PMID Version="1">25576341</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2018 Jan 5;9(3):604-613</RefSource>                <PMID Version="1">29483966</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Oct 27;8(61):104206-104215</RefSource>                <PMID Version="1">29262633</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Mol Med. 2018 Apr;41(4):1958-1966</RefSource>                <PMID Version="1">29328428</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cytokine-induced apoptosis inhibitor 1</Keyword>            <Keyword MajorTopicYN="N">Human mammaglobin</Keyword>            <Keyword MajorTopicYN="N">Micro-ribonucleic acid-143-3p</Keyword>            <Keyword MajorTopicYN="N">Multiple drug resistance</Keyword>            <Keyword MajorTopicYN="N">Triple negative breast neoplasms</Keyword>        </KeywordList>        <CoiStatement>CONFLICT OF INTEREST: The authors declare that they have no competing interests.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30275853</ArticleId>            <ArticleId IdType="doi">10.4048/jbc.2018.21.e40</ArticleId>            <ArticleId IdType="pmc">PMC6158160</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>